Published in Eur Addict Res on August 28, 2012
Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci (2015) 1.04
Current and Future Prospects for Epigenetic Biomarkers of Substance Use Disorders. Genes (Basel) (2015) 0.83
Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One (2014) 0.80
Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.77
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res (2010) 2.45
Socioeconomic status and depression during and after pregnancy in the Franconian Maternal Health Evaluation Studies (FRAMES). Arch Gynecol Obstet (2013) 2.06
Managing an effective treatment for neuroleptic malignant syndrome. Crit Care (2007) 1.73
Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry (2009) 1.64
Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem (2006) 1.54
Use-dependent inhibition of synaptic transmission by the secretion of intravesicularly accumulated antipsychotic drugs. Neuron (2012) 1.51
Epigenetic DNA hypermethylation of the HERP gene promoter induces down-regulation of its mRNA expression in patients with alcohol dependence. Alcohol Clin Exp Res (2006) 1.51
Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. J Alzheimers Dis (2009) 1.49
Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging (2004) 1.48
DNA hypermethylation of the alpha synuclein promoter in patients with alcoholism. Neuroreport (2005) 1.46
Drug-induced psychosis after long-term treatment with levetiracetam. Can J Psychiatry (2004) 1.46
Repetitive transcranial magnetic stimulation influences mood in healthy male volunteers. J Psychiatr Res (2011) 1.46
Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nat Med (2013) 1.36
Therapeutic approaches to Alzheimer's disease. Brain (2006) 1.34
Global DNA methylation is influenced by smoking behaviour. Eur Neuropsychopharmacol (2008) 1.29
Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem (2007) 1.28
Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis (2004) 1.27
International quality control survey of neurochemical dementia diagnostics. Neurosci Lett (2006) 1.26
CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain (2006) 1.25
Non-drug therapies for dementia: an overview of the current situation with regard to proof of effectiveness. Dement Geriatr Cogn Disord (2003) 1.17
Peer review versus editorial review and their role in innovative science. Theor Med Bioeth (2012) 1.16
Association of SORL1 gene variants with Alzheimer's disease. Brain Res (2009) 1.14
Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. J Mol Neurosci (2004) 1.13
Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm (Vienna) (2009) 1.10
Promoter specific methylation of the dopamine transporter gene is altered in alcohol dependence and associated with craving. J Psychiatr Res (2008) 1.10
Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging (2007) 1.10
Influence of brain-derived neurotrophic-factor and apolipoprotein E genetic variants on hippocampal volume and memory performance in healthy young adults. J Neural Transm (Vienna) (2010) 1.09
A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats. Brain (2013) 1.07
Self-enucleation in drug-related psychosis. Ophthalmologica (2002) 1.06
Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer's disease. Neurosci Lett (2008) 1.04
Daily variations of homocysteine concentration may influence methylation of DNA in normal healthy individuals. Chronobiol Int (2007) 1.03
Optimized data preprocessing for multivariate analysis applied to 99mTc-ECD SPECT data sets of Alzheimer's patients and asymptomatic controls. J Cereb Blood Flow Metab (2010) 1.03
Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol (2003) 1.02
The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis (2012) 1.02
Homocysteine in tear fluid of patients with pseudoexfoliation glaucoma. J Glaucoma (2007) 1.02
Alpha-synuclein protein levels are increased in alcoholic patients and are linked to craving. Alcohol Clin Exp Res (2005) 1.01
Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol Psychiatry (2004) 1.01
Ghrelin levels are increased in alcoholism. Alcohol Clin Exp Res (2005) 1.00
Elevated alpha synuclein mRNA levels are associated with craving in patients with alcoholism. Biol Psychiatry (2004) 1.00
Auricular transcutaneous electrical nerve stimulation in depressed patients: a randomized controlled pilot study. J Neural Transm (Vienna) (2012) 0.99
Quantitative modeling of selective lysosomal targeting for drug design. Eur Biophys J (2008) 0.99
Epigenetic dysregulation of dopaminergic genes in eating disorders. Int J Eat Disord (2010) 0.99
Cerebrospinal fluid leakage--reliable diagnostic methods. Clin Chim Acta (2011) 0.98
N-methyl-D-aspartate 2b receptor subtype (NR2B) promoter methylation in patients during alcohol withdrawal. J Neural Transm (Vienna) (2009) 0.98
DNA methylation of the POMC gene promoter is associated with craving in alcohol dependence. J Neural Transm (Vienna) (2010) 0.97
Secretory sphingomyelinase in health and disease. Biol Chem (2015) 0.97
Microstructural abnormalities of the posterior thalamic radiation and the mediodorsal thalamic nuclei in females with anorexia nervosa--a voxel based diffusion tensor imaging (DTI) study. J Psychiatr Res (2012) 0.97
Cortical activity associated with auditory hallucinations. Neuroreport (2004) 0.96
Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J Neurochem (2007) 0.96
Low digit ratio 2D:4D in alcohol dependent patients. PLoS One (2011) 0.96
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96
Systematic heterogeneity of fractional vesicle pool sizes and release rates of hippocampal synapses. Biophys J (2011) 0.96
Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel Abeta species. Proteomics (2007) 0.96
CNS BOLD fMRI effects of sham-controlled transcutaneous electrical nerve stimulation in the left outer auditory canal - a pilot study. Brain Stimul (2013) 0.96
Hippocampal volume differences between healthy young apolipoprotein E ε2 and ε4 carriers. J Alzheimers Dis (2011) 0.96
Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry (2003) 0.95
C677T variant in the methylentetrahydrofolate reductase gene is a genetic risk factor for primary open-angle glaucoma. Am J Ophthalmol (2005) 0.95
Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J Alzheimers Dis (2011) 0.95
The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun Mass Spectrom (2003) 0.95
Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease. Psychiatry Res (2010) 0.95
Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons. Brain Res (2005) 0.95
Transient increase of plasma concentrations of amyloid β peptides after electroconvulsive therapy. Brain Stimul (2011) 0.94
Elevated homocysteine levels in aqueous humor of patients with pseudoexfoliation glaucoma. Am J Ophthalmol (2004) 0.94
Sex hormone activity in alcohol addiction: integrating organizational and activational effects. Prog Neurobiol (2011) 0.94
Key physiological parameters dictate triggering of activity-dependent bulk endocytosis in hippocampal synapses. PLoS One (2012) 0.93
The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer's dementia. Psychiatry Res (2010) 0.93
Non-pharmacological, multicomponent group therapy in patients with degenerative dementia: a 12-month randomizied, controlled trial. BMC Med (2011) 0.92
Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype. J Alzheimers Dis (2010) 0.91
Epigenetic regulation and gene expression of vasopressin and atrial natriuretic peptide in alcohol withdrawal. Psychoneuroendocrinology (2008) 0.91
Quantification of fatty acid ethyl esters (FAEE) and ethyl glucuronide (EtG) in meconium from newborns for detection of alcohol abuse in a maternal health evaluation study. Anal Bioanal Chem (2010) 0.91
Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. J Neural Transm (Vienna) (2009) 0.91
Evidence of increased homocysteine levels in alcoholism: the Franconian alcoholism research studies (FARS). Alcohol Clin Exp Res (2005) 0.90
Epigenetic down regulation of nerve growth factor during alcohol withdrawal. Addict Biol (2011) 0.90
Evidence of an association of leptin serum levels and craving in alcohol dependence. Psychoneuroendocrinology (2006) 0.90
CSF markers in amyotrophic lateral sclerosis. J Neural Transm (Vienna) (2012) 0.90
Daytime impairment and neurodegeneration in OSAS. Sleep (2006) 0.89
Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease. J Alzheimers Dis (2012) 0.89